Interplay between Negative Regulators of Type I Interferon and HIV control
I 型干扰素负调节因子与 HIV 控制之间的相互作用
基本信息
- 批准号:9411359
- 负责人:
- 金额:$ 25.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-10 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAnti-Inflammatory AgentsAnti-inflammatoryAntiviral AgentsBiologyBloodCD4 Positive T LymphocytesCRISPR/Cas technologyCell LineCellsCodeCommunicable DiseasesComplementDNA VirusesDataDefense MechanismsDiseaseFibroblastsGene ExpressionGene Expression ProfileGenesGeneticGenetic TranscriptionGerm-Line MutationHIVHIV InfectionsHIV-1HIV-2HealthHerpesvirus 1Highly Active Antiretroviral TherapyHumanISG15 geneImmuneImmunityIndividualInfectionInfection ControlInflammationInterferon Type IInterferonsInterventionInvadedInvestigationKnock-outLife Cycle StagesMolecularMolecular MimicryMolecular ProfilingMutationPathogenesisPatientsPatternPeptide HydrolasesPhenotypePredispositionPrincipal InvestigatorProcessProteinsRNA VirusesRegulationReporterResistanceRift Valley fever virusRoleSeriesSignal TransductionTechnologyTestingTherapeutic InterventionUbiquitinVariantViralVirusautoinflammationcell typecytokineexperimental studygenetic signatureimprovedinfluenzavirusmutantnano-stringnovelpathogenpreventresponsetoolviral resistance
项目摘要
PROJECT SUMMARY/ABSTRACT
Humans possess multi-layered defenses against invading pathogens. One of the first antiviral defense
mechanisms is the induction of Type I Interferons (IFNs). IFNs are cytokines with well-defined antiviral
activities. They induce transcription of hundreds of IFN stimulated genes (ISGs). We discovered and
characterized six individuals with complete ISG15 deficiency. The cells of these patients presented with mild
IFN auto-inflammation and decreased susceptibility to a broad spectrum of viruses. Thus, ISG15 acts as an
anti-inflammatory as well as a proviral molecule. Our studies ascribed ISG15 a role of negative regulator of
IFN signaling explaining these two phenotypes. More recently we also discovered five patients with a
complete USP18 deficiency, a master negative regulator of IFN signaling.
This proposal is built around the hypothesis that germ line mutations in negative regulators of IFN afford
increased control of HIV infection. Our preliminary data indicate that HIV is restricted in IFN primed cells from
ISG15 deficient patients. We propose test if USP18 deficient individuals' cells also have increased resistance
to HIV. Naturally deficient patient cell line will be complemented with a series of ISG15 and USP18 variants in
order to discriminate between negative regulation and ISGylation as underlying mechanism of action. We will
also determine what step in the HIV life cycle is specifically targeted in the context of ISG15/USP18 deficiency.
We will also evaluate whether primary CD4+ T cells deficient in ISG15 or USP18 control HIV better compared
to control cells and investigate the extent to which cells from HIV infected patients that spontaneously control
infection display expression signatures of ISGs that mimic the unique expression patterns found in patients
with deleterious mutations in ISG15 and USP18. These studies have the potential to radically change our
understanding of naturally occuring HIV control and point to new interventions suitable to yield functional cures
for HIV/AIDS disease.
项目摘要/摘要
人类对入侵的病原体具有多层次的防御能力。最早的抗病毒防御之一
机制是诱导I型干扰素(IFN)。干扰素是一种细胞因子,具有明确的抗病毒作用
活动。它们诱导数百个干扰素刺激基因(ISGs)的转录。我们发现并
具有6个完全缺乏ISG15的个体的特征。这些患者的细胞表现出轻微的
干扰素自发性炎症,降低对广谱病毒的易感性。因此,ISG15充当
抗炎和前病毒分子。我们的研究认为ISG15是一种负调控因子
干扰素信号可以解释这两种表型。最近,我们还发现五名患者患有
完全性USP18缺乏症,干扰素信号的主要负调节因子。
这一建议是建立在这样一个假设之上的,即干扰素的负调控因子中的生殖系突变
加强对艾滋病毒感染的控制。我们的初步数据表明,HIV在干扰素诱导的细胞中受到限制
ISG15缺乏者。我们建议测试USP18缺陷个体的细胞是否也增加了抵抗力
为艾滋病毒干杯。天然缺陷的患者细胞系将被一系列ISG15和USP18变异体补充
以便区分负调控和ISG化作为潜在的作用机制。我们会
还应确定在ISG15/USP18缺乏的情况下,艾滋病毒生命周期中的哪个步骤是专门针对的。
我们还将评估与ISG15和USP18缺陷的原始CD4+T细胞相比,哪个控制HIV的效果更好
控制细胞并调查HIV感染患者的细胞自发控制的程度
感染显示ISGs的表达特征,模仿在患者中发现的独特表达模式
具有ISG15和USP18的有害突变。这些研究有可能从根本上改变我们的
了解自然发生的艾滋病毒控制,并指出适合产生功能性治疗的新干预措施
用于艾滋病毒/艾滋病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dusan Bogunovic其他文献
Dusan Bogunovic的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dusan Bogunovic', 18)}}的其他基金
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)
纽约地区先天性缺陷免疫资源倡议联盟 (NY-ROYAL)
- 批准号:
10554965 - 财政年份:2023
- 资助金额:
$ 25.43万 - 项目类别:
Immunologic and Predictive Features of MIS-C
MIS-C 的免疫学和预测特征
- 批准号:
10667530 - 财政年份:2022
- 资助金额:
$ 25.43万 - 项目类别:
Transient Gene Therapy as Broad Spectrum Antiviral
瞬时基因疗法作为广谱抗病毒药物
- 批准号:
10324302 - 财政年份:2021
- 资助金额:
$ 25.43万 - 项目类别:
Role of SARS-CoV-2-mediated Type I IFN antagonism in individuals with Down Syndrome
SARS-CoV-2 介导的 I 型 IFN 拮抗作用在唐氏综合症患者中的作用
- 批准号:
10158984 - 财政年份:2020
- 资助金额:
$ 25.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10206016 - 财政年份:2020
- 资助金额:
$ 25.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10058607 - 财政年份:2020
- 资助金额:
$ 25.43万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10120982 - 财政年份:2020
- 资助金额:
$ 25.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10443794 - 财政年份:2020
- 资助金额:
$ 25.43万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10655435 - 财政年份:2020
- 资助金额:
$ 25.43万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10461962 - 财政年份:2020
- 资助金额:
$ 25.43万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 25.43万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 25.43万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 25.43万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 25.43万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 25.43万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 25.43万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 25.43万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 25.43万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 25.43万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 25.43万 - 项目类别: